GTMB 7 - Gene Therapy & Molecular Biology

More documents

Recommendations

Info

David et al: Current status and future direction of fetal gene therapyThe decision to participate in a fetal gene therapy trialwould occur close to the time of prenatal diagnosis of thecondition. The parents may hear information in a highlybiased way and not consider the risk to future pregnancies.It will be important to ensure that parents are adequatelycounselled and understand these issues before agreeing totake part in any future research. The general publicremains concerned that ethical discussion about issuessuch as gene therapy, cloning and the Human GenomeProject are falling behind the technology (Brown, 2000). Itis therefore important to provide adequate informationwhich will allow the public to understand the risks andbenefits of these novel techniques and to enable aneducated involvement in the decision-making processalong with health professionals. This will also helpindividuals to give informed consent as these proceduresbecome used in clinical practice.VII. ConclusionsFetal gene therapy offers the potential forobstetricians and gene therapists not only to diagnose butalso to treat inherited genetic disease. However, for thetreatment to be acceptable, it must offer advantages overpostnatal gene therapy, be safe for both mother and fetus,and preferably avoid germ-line transmission. Currently, inutero gene therapy remains an experimental procedure.But in the future, better understanding of the developmentof genetic disease in the fetus, and improvements in vectordesign and targeting of fetal tissues should allow thistechnology to move into clinical practice.ReferencesAiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A,Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E,Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG,Bordignon C (2002) Correction of ADA-SCID by stem cellgene therapy combined with nonmyeloablative conditioning.Science 296, 2410-2413.Akiyama M (1998) Severe congenital ichthyosis of the neonate.Int J Dermatol 37, 722-728.Anderson CC, Carroll JM, Gallucci S, Ridge JP, Cheever AW,Matzinger P (2001) Testing time-, ignorance-, and dangerbasedmodels of tolerance. J Immunol 166, 3663-3671.Badalian SS, Chao CR, Fox HE, Timor TI (1993) Fetalbreathing-related nasal fluid flow velocity in uncomplicatedpregnancies. Am J Obstet Gynecol 169, 563-567.Badawi N, Kurinczuk JJ, Keogh JM, Alessandri LM, O'SullivanF, Burton PR, Pemberton PJ, Stanley FJ (1998) Intrapartumrisk factors for newborn encephalopathy: the WesternAustralian case-control study. BMJ 317, 1549-1553.Baldeschi C, Gache Y, Rattenholl A, Bouille P, Danos O,Ortonne JP, Bruckener-Tuderman L, Meneguzzi G (2003).Genetic correction of canine dystrophic epidermolysisbullosa mediated by retroviral vectors. Hum Mol Genet 12,1897-1905.Barcroft J, Barron (1946) Observations upon the form andrelations of the maternal and fetal vessels in the placenta ofthe sheep. Anat Rec 94, 569-595.Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA,Robinson JS (1993) Fetal nutrition and cardiovasculardisease in adult life. Lancet 341, 938-941.Baumgartner TL, Baumgartner BJ, Hudon L, Moise KJ (1999)Ultrasonographically guided direct gene transfer in utero:Successful induction of β-galactosidase in a rabbit model.Am J Obstet Gynecol 181, 848-852.Benirschke K, Kaufmann P (1990) Placental types. Pathology ofthe human placenta. Springer-Verlag, New York.Bennett M, Galan H, Owens G, Dewey R, Banks R, Hobbins J,Accurso F, Schaack J (2001) In utero gene delivery byintraamniotic injection of a retroviral vector producer cellline in a nonhuman primate model. Hum Gene Ther 12,1857-1865.Bigger B, Coutelle C (2001) Perspectives on gene therapy forcystic fibrosis airway disease. Biodrugs 15, 615-634.Billingham RE, Brent L, Medawar PB (1956) Quantitativestudies on tissue transplantation immunity III Activelyacquired tolerance. Phil Trans R Soc (London) B239, 357-369.Binns R (1967) Bone marrow and lymphoid cell injection of thepig fetus resulting in transplantation tolerance or immunity,and immunoglobulin production. Nature 214, 179-180.Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T,Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P,Greenblatt JJ, Rosenberg SA, Klein H, Berger M, MullenCA, Ramsey WJ, Muul L, Morgan RA, French Anderson W(1995) T lymphocyte-directed gene therapy for ADA- SCID:initial trial results after 4 years. Science 270, 475-480.Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G,Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P,Ugazio AG, Mavilio F (1995) Gene therapy in peripheralblood lymphocytes and bone marrow for ADAimmunodeficientpatients. Science 270, 470-475.Boué A, Muller F, Nezelof C, Oury JF, Duchatel F, Dumez Y,Aubry MC, Boue J (1986) Prenatal diagnosis in 200pregnancies with a 1-in-4 risk of cystic fibrosis. Hum Genet74, 288-297.Boyle MP, Enke RA, Adams RJ, Guggino WB, Zeitlin PL (2001)In utero AAV-mediated gene transfer to rabbit pulmonaryepithelium. Mol Ther 4, 115-121.Brandt ML, Moise KJJ, Eckert JW, Johnson L, Waltrip T, SaadeG, Wu Y, Finegold MJ (1997) Transuterine puncture of thefetal stomach provides access to the small bowel in therabbit. J Invest Surg 10, 41-46.Brosens JJ, Pijnenborg R, Brosens IA ( 2002) The myometrialjunctional zone spiral arteries in normal and abnormalpregnancies: a review of the literature. Am J ObstetGynecol 187, 1416-1423.Brown P (2000) Regulations not keeping up with developmentsin genetics, says poll. BMJ 321, 1369.Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW,Roberts JL, Myers LA, Ward FE (1999) Hematopoietic stemcelltransplantation for the treatment of severe combinedimmunodeficiency. New Engl J Med 340, 508-516.Buckley SMK, Waddington SN, Jezzard S, Themis M, ColledgeWH, Coutelle C (2003) Intra-amniotic application of CFTRexpressingadenovirus does not reverse cystic fibrosisphenotype in inbred Cftr-knockout mice. Mol Ther 7, S200.Burger IM, Wilfond BS (2000) Limitations of informed consentfor in utero gene transfer research: implications forinvestigators and institutional review boards. Hum GeneTher 11, 1057-1063.Burlet P, Huber C, Bertrandy S, Ludosky MA, Zwaenepoel I,Clermont O, Roume J, Delezoide AL, Cartaud J, Munnich A,Lefebvre S (1998) The distribution of SMN protein complexin human fetal tissues and its alteration in spinal muscularatrophy. Hum Mol Genet 7, 1927-1933.Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, HaasDL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM(1999) Stable transduction of quiescent CD34(+)CD38(-)human hematopoietic cells by HIV-1-based lentiviralvectors. Proc Natl Acad Sci 96, 2988-2993.202
Gene Therapy and Molecular Biology Vol 7, page 203Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F,Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova J,Bousso P, Le Deist F, Fischer A (2000) Gene therapy ofhuman severe combined immunodeficiency (SCID)-X1disease. Science 288, 669-672.Cavazzana-Calvo M, Hacein-Bey S, Yates F, De Villartay JP, LeDeist F, Fischer A (2001) Gene therapy of severe combinedimmunodeficiencies. J Gene Med 3, 201-206.Challita PM, Kohn DB (1994) Lack of expression from aretroviral vector after transduction of murine hematopoieticstem cells is associated with methylation in vivo. Proc NatlAcad Sci 91, 2567-2571.Chamberlain JS (2002) Gene therapy of muscular dystrophy.Hum Mol Genet 11, 2355-2362.Chao H, Samulski RJ, Bellinger D, Monahan PE, Nichols T,Walsh CE (1999) Persistent expression of canine factor IX inhemophilia B canines. Gene Ther 6, 1695-1704.Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, ClemensPR (1997) Persistence in muscle of an adenoviral vector thatlacks all viral genes. Proc Natl Acad Sci 94, 1645-1650.Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, FinlayD, Barcova M, Cannon PM, Mazurek C, Woodley DT (2002)Restoration of type VII collagen expression and function indystrophic epidermolysis bullosa. Nat Genet 32, 670-675.Cheng SH, Smith AE (2003) Gene therapy progress andprospects: gene therapy of lysosomal storage disorders. GeneTher 10, 1275-1281.Chinnaiya A, Venkat A, Dawn C, Chee WY, Choo KB, GoleLA, Meng CT (1998) Intraheptatic vein fetal blood sampling:current role in prenatal diagnosis. J Obstet Gynaecol Res24, 239-246.Christensen G, Minamisawa S, Gruber PJ, Wang Y, Chien KR(2000) High-efficiency, long-term cardiac expression offoreign genes in living mouse embryos and neonates.Circulation 101, 178-184.Cole FS, Hamvas A, Nogee LM (2003) Genetic disorders ofneonatal respiratory function. Ped Res 50, 157-162.Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK(1995) High-titer packaging cells producing recombinantretroviruses resistant to human serum. J Virol 69, 7430-7436.Coutelle C, Douar A-M, Colledge WH, Froster U (1995) Thechallenge of fetal gene therapy. Nat Med 1, 864-866.Coutelle C, Rodeck C (2002) On the scientific and ethical issuesof fetal somatic gene therapy. Gene Ther 9, 670-673.Crawford TO, Pardo CA (1996) The neurobiology of childhoodspinal muscular atrophy. Neurobiol Dis 3, 97-110.Daly TM, Vogler C, Levy B, Haskins ME, Sands MS (1999)Neonatal gene transfer leads to widespread correction ofpathology in a murine model of lysosomal storage disease.Proc Natl Acad Sci 96, 2296-2300.David AL, Cook T, Waddington S, Peebles D, Nivsarkar M,Knapton H, Miah M, Dahse T, Noakes D, Schneider H,Rodeck C, Coutelle C, Themis M (2003a) Ultrasound guidedpercutaneous delivery of adenoviral vectors encoding β-galactosidase and human factor IX genes to early gestationfetal sheep in utero. Hum Gene Ther 14, 353-364.David AL, Peebles DM, Gregory L, Themis M, Cook T, CoutelleC, Rodeck C, (2003b) Percutaneous ultrasound-guidedinjection of the trachea in fetal sheep: a novel technique totarget the fetal airways. Fetal Diagn Ther 18, 385-390.Deconinck N, Ragot T, Marechal G, Perricaudet M, Gillis JM(1996) Functional protection of dystrophic mouse (mdx)muscles after adenovirus-mediated transfer of a dystrophinminigene. Proc Natl Acad Sci 93, 3570-3574.DiDonato CJ, Parks RJ, Kothary R (2003) Development of agene therapy strategy for the restoration of survival motorneuron protein expression: implications for spinal muscularatrophy therapy. Hum Gene Ther 14, 179-188.Douar A-M, Adebakin S, Themis M, Pavirani A, Cook T,Coutelle C (1997) Foetal gene delivery in mice by intraamnioticadministration of retroviral producer cells andadenovirus. Gene Ther 4, 883-890.Douar A-M, Themis M, Sandig V, Friedmann T, Coutelle C(1996) Effect of amniotic fluid on cationic lipid mediatedtransfection and viral infection. Gene Ther 3, 789-796.Dziegielewska KM, Ek J, Habgood MD, Saunders NR (2001)Development of the choroid plexus. Microsc Res Tech 52,5-20.Emery AEH (1993) Duchenne muscular dystrophy. OxfordUniversity Press.Emery AEH (2002) The muscular dystrophies. Lancet 359, 687-695.Engelhardt JF, Schlossberg H, Yankaskas JR, Dudus L (1995)Progenitor cells of the adult human airway involved insubmucosal gland development. Development 121, 2031-2046.Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR,Boucher RC, Cohn JA, Wilson JM (1992) Submucosalglands are the predominant site of CFTR expression in thehuman bronchus. Nat Genet 2, 240-248.Engelstädter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen RA, Stitz J, Cichutek K (2001)Targeted gene transfer to lymphocytes using murineleukaemia virus vectors pseudotyped with spleen necrosisvirus envelope proteins. Gene Ther 8, 1202-1206.Flake AW, Roncarolo MG, Puck JM, Almeida-Porada G, EvansMI, Johnson MP, Abella EM, Harrison DD, Zanjani ED(1996) Treatment of X-linked severe combinedimmunodeficiency by in utero transplantation of paternalbone marrow. N Engl J Med 335, 1806-1810.Fletcher JC, Richter G (1996) Human fetal gene therapy: moraland ethical questions. Hum Gene Ther 7, 1605-1614.Fowden AL (1995) Nutrient requirements for normal fetalgrowth and metabolism. In: Hanson MA, Spencer JAD,Rodeck CH (Eds.), Fetus and Neonate: Physiology andClinical Applications: Growth. Cambridge University Press,Cambridge, pp. 31-56.Friedmann T (2003) Gene therapy's new era: a balance ofunequivocal benefit and unequivocal harm. Mol Ther 8, 5-7.Furie B, Limentani SA, Rosenfield CG (1994) A practical guideto the evaluation and treatment of hemophilia. Blood 84, 3-9.Gaillard D, Ruocco S, Lallemand A, Dalemans W, Hinnrasky J,Puchelle E (1994) Immunohistochemical localization ofcystic fibrosis transmembrane conductance regulator inhuman fetal airway and digestive mucosa. Ped Res 36, 137-143.Galan HL, Bennett ML, Tyson RW, Owens G, Ragnault TR,Accurso F, Robbins JC, Schaack J (2002) Inefficienttransduction of sheep in utero after intra-amniotic injectionof retroviral producer cells. Am J Obstet Gynecol 187, 469-474.Gansbacher B, European Society of Gene Therapy (2003) Reportof a second serious adverse event in a clinical trial of genetherapy for X-linked severe combined immune deficiency(X-SCID). Position of the European Society of GeneTherapy (ESGT). J Gene Med 5, 261-262.Geipel A, Berg C, Germer U, Krapp M, Kohl M, Gembruch U(2002) Mucopolysaccharidosis VII (Sly disease) as a causeof increased nuchal translucency and non-immune fetalhydrops: study of a family and technical approach to prenataldiagnosis in early and late pregnancy. Prenat Diagn 22, 493-495.203
Page 7 and 8:
Instructions to authors:Gene Therap
Page 9:
Please submit an electronic version
Page 12:
103-111 ResearchArticle113-133 Revi
Page 17 and 18:
Gene Therapy and Molecular Biology
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77:
Page 80 and 81:
Epperly et al: Late injection of Mn
Page 82 and 83:
Epperly et al: Late injection of Mn
Page 84 and 85:
Goldberg-Cohen et al: Regulation of
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Gascón-Irún et al: Gene therapy a
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Suzuki et al: Regulation of the Sp/
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Li et al: MET amplification in live
Page 116 and 117:
Li et al: MET amplification in live
Page 118 and 119:
Chavakis et al: Leukocyte adhesion
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Sanlioglu et al: Adenovirus mediate
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
George et al: Gene therapy for vasc
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167: George et al: Gene therapy for vasc
Page 168 and 169: Zhang et al: Angiogenic Gene Therap
Page 182 and 183: Xu et al: G-CSF receptor-mediated S
Page 188 and 189: Burek et al: Calcium induced cell d
Page 196 and 197: David et al: Current status and fut
Page 226 and 227: Stoll et al: The role of EBV and ge
Page 236 and 237: Maruyama et al: Kidney-targeted pla
Page 244 and 245: Kren et al: Hepatocyte-targeted del
Page 254 and 255: Zeng: PRL-3 as a target for cancer
Page 260 and 261: Latchman: Protective effect of heat
Page 266 and 267:
Latchman: Protective effect of heat
Page 268 and 269:
Latchman: Protective effect of heat
Page 270 and 271:
Cai et al: Lung cancer gene therapy
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309:
show all

GTMB 7 - Gene Therapy & Molecular Biology

Create successful ePaper yourself

Delete template?

Save as template?